Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Sep 20;28(11):1279-1289.
doi: 10.1093/eurjpc/zwaa047.

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study

Kausik K Ray  1 , Bart Molemans  2 , W Marieke Schoonen  3 , Periklis Giovas  4 , Sarah Bray  5 , Gaia Kiru  6 , Jennifer Murphy  6 , Maciej Banach  7   8   9 , Stefano De Servi  10 , Dan Gaita  11 , Ioanna Gouni-Berthold  12 , G Kees Hovingh  13 , Jacek J Jozwiak  14 , J Wouter Jukema  15 , Robert Gabor Kiss  16 , Serge Kownator  17 , Helle K Iversen  18   19 , Vincent Maher  20   21 , Luis Masana  22 , Alexander Parkhomenko  23 , André Peeters  24 , Piers Clifford  25 , Katarina Raslova  26 , Peter Siostrzonek  27 , Stefano Romeo  28   29   30 , Dimitrios Tousoulis  31 , Charalambos Vlachopoulos  31 , Michal Vrablik  32 , Alberico L Catapano  33 , Neil R Poulter  6 ; DA VINCI study
Affiliations
Observational Study

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study

Kausik K Ray et al. Eur J Prev Cardiol. .

Abstract

Aims: To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement.

Methods and results: An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52-56] achieved their risk-based 2016 goal and 33% (95% CI 32-35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate-high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination).

Conclusion: Gaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.

Keywords: Cholesterol; Guidelines; Lipids; Registry; Statins.

PubMed Disclaimer

Publication types

MeSH terms